OralParenteralTopicalDosed ingredientTherapeutic flag
Cosmetic cross-reference
Acetaminophen
CAS 103-90-2
Acetaminophen (CAS 103-90-2) is a Phase 4 pharmaceutical compound with 18 bioactivity targets and 27,587 adverse event associations.
SOURCE
NLM DailyMed
Label records
3
SOURCE
EMBL-EBI ChEMBL
Bioactivity
27
SOURCE
DrugCentral
Adverse signals
27,587
SOURCE
IUPHAR/BPS
PubMed IDs
22
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Acetaminophen
CAS Number
103-90-2
UNII
362O9ITL9D
InChIKey
RZVAJINKPMORJF-UHFFFAOYSA-N
ChEMBL ID
CHEMBL112
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
PanadolTylenolAnacinExcedrinFeverallNorcoRedutempTenconAcephenUltracet
black box warningdosed ingredientoralparenteraltherapeutic flagtopical
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL112 | Small molecule
SOURCE
Ingredients table / CosIng profile
same-CAS cross-reference
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
SOURCE
NLM DailyMed
3 label rows
Drug Label Active Ingredients
Active ingredient and active moiety rows from source drug product labels.
| Product | Ingredient | Active Moiety | Effective |
|---|---|---|---|
| Pain Reliever | ACETAMINOPHEN 362O9ITL9D |
ACETAMINOPHEN | 20260506 |
| Daytime Cold and Flu Multi Symptom mini softgels | ACETAMINOPHEN 362O9ITL9D |
ACETAMINOPHEN | 20260505 |
| MAX relief junior Grape | ACETAMINOPHEN 362O9ITL9D |
ACETAMINOPHEN | 20260505 |
SOURCE
EMBL-EBI ChEMBL
27 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 29056.41964285714 nM | 112 | - |
| - | Potency | 19035.260000000002 nM | 19 | - |
| - | Ki | 17145.625 nM | 16 | - |
| - | IC50 | 33911.74 nM | 12 | - |
| - | Kd | 106306 nM | 5 | - |
| - | MIC | 640666.6666666666 nM | 3 | - |
| - | EC50 | 2 ug.mL-1 | 1 | - |
| - | GI50 | 1002000 nM | 1 | - |
| Prostaglandin G/H synthase 2 Enzyme |
IC50 | 4.31 | - | Homo sapiens |
| Transient receptor potential cation channel subfamily V member 1 Ion channel |
OPENER | - | - | Homo sapiens |
| Nuclear receptor subfamily 1 group I member 3 Nuclear hormone receptor |
- | - | - | Homo sapiens |
| Carbonic anhydrase 2 Enzyme |
Ki | 5.21 | - | Homo sapiens |
| Carbonic anhydrase 1 Enzyme |
Ki | 5 | - | Homo sapiens |
| Carbonic anhydrase 4 Enzyme |
Ki | 4.94 | - | Homo sapiens |
| Carbonic anhydrase 9 Enzyme |
Ki | 4.15 | - | Homo sapiens |
| Carbonic anhydrase 12 Enzyme |
Ki | 5.39 | - | Homo sapiens |
| Carbonic anhydrase 7 Enzyme |
Ki | 5.04 | - | Homo sapiens |
| Carbonic anhydrase 3 Enzyme |
Ki | 5.15 | - | Homo sapiens |
| Carbonic anhydrase 14 Enzyme |
Ki | 4.97 | - | Homo sapiens |
| Arachidonate 5-lipoxygenase-activating protein Cytosolic other |
IC50 | 4.36 | - | Homo sapiens |
| Transient receptor potential cation channel subfamily V member 4 Ion channel |
IC50 | 6.52 | - | Homo sapiens |
| Arachidonate 15-lipoxygenase Enzyme |
IC50 | 4.547 | - | Oryctolagus cuniculus |
| Carbonic anhydrase 13 Enzyme |
Ki | 4.52 | - | Mus musculus |
| Carbonic anhydrase 15 Enzyme |
Ki | 5.03 | - | Mus musculus |
| Myoglobin Unclassified |
IC50 | 5.64 | - | Homo sapiens |
| Transient receptor potential cation channel subfamily V member 4 Ion channel |
IC50 | 6.52 | - | Homo sapiens |
| Cannabinoid receptor 1 GPCR |
AGONIST | - | - | Homo sapiens |
SOURCE
DrugCentral
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Toxicity to various agents | 16522 | 4256.034 | 10070863 |
| Overdose | 8621 | 2643.79 | 10033295 |
| Acute hepatic failure | 2937 | 2492.089 | 10000804 |
| Intentional overdose | 5691 | 2435.809 | 10022523 |
| Completed suicide | 8474 | 2132.151 | 10010144 |
| Drug ineffective | 16528 | 1516.565 | 10013709 |
| Analgesic drug level increased | 828 | 1503.261 | 10060942 |
| Hepatocellular injury | 2464 | 1162.604 | 10019837 |
| Infusion related reaction | 8886 | 1022.099 | 10051792 |
| Blood pressure fluctuation | 3427 | 887.274 | 10005746 |
| Poisoning deliberate | 1278 | 861.478 | 10036000 |
| Suicide attempt | 3469 | 835.261 | 10042464 |
| Exposure to toxic agent | 846 | 832.784 | 10053487 |
| Product dose omission issue | 3227 | 559.18 | 10084406 |
| Drug resistance | 119 | 529.999 | 10059866 |
| Blood pressure diastolic abnormal | 1406 | 505.794 | 10005736 |
| Intentional product misuse | 3135 | 501.365 | 10074903 |
| Metabolic acidosis | 2720 | 497.261 | 10027417 |
| Cholestasis | 1920 | 464.315 | 10008635 |
| Hepatotoxicity | 2122 | 450.45 | 10019851 |
| Blood pressure systolic increased | 2721 | 448.557 | 10005760 |
| Injection site pain | 1236 | 437.703 | 10022086 |
| Heart rate decreased | 2715 | 415.428 | 10019301 |
| Oxygen saturation decreased | 4064 | 409.573 | 10033318 |
| Blood pressure systolic abnormal | 1202 | 409.514 | 10005757 |
| Blood pressure increased | 6322 | 386.456 | 10005750 |
| Accidental overdose | 1547 | 367.91 | 10000381 |
| Device expulsion | 58 | 336.208 | 10012578 |
| Disease progression | 2435 | 324.698 | 10061818 |
| Hepatic cytolysis | 1103 | 318.941 | 10049199 |
| Therapeutic product effect incomplete | 1669 | 313.022 | 10082200 |
| Sinusitis | 6026 | 311.971 | 10040753 |
| Hepatic failure | 2059 | 302.624 | 10019663 |
| Coagulopathy | 1339 | 295.18 | 10009802 |
| Somnolence | 6434 | 289.473 | 10041349 |
| Wrong technique in product usage process | 733 | 286.325 | 10076573 |
| Hepatic necrosis | 539 | 282.385 | 10019692 |
| Treatment failure | 2829 | 270.996 | 10066901 |
| Cardiac failure congestive | 1578 | 259.933 | 10007559 |
| Coma | 2825 | 251.968 | 10010071 |
| Hospitalisation | 1289 | 246.575 | 10054112 |
| Anion gap | 227 | 244.685 | 10002522 |
| Hepatitis | 1779 | 238.437 | 10019717 |
| Hepatitis acute | 688 | 235.611 | 10019727 |
| Injection site erythema | 767 | 227.206 | 10022061 |
| Myocardial infarction | 2289 | 224.928 | 10028596 |
| Heart rate increased | 3440 | 224.888 | 10019303 |
| Vomiting | 15317 | 220.352 | 10047700 |
| Throat irritation | 1507 | 219.583 | 10043521 |
| Lower respiratory tract infection | 3889 | 219.097 | 10024968 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR/BPS
3 interactions
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| COX-1 PTGS1 |
Inhibition | 3.940000057220459 pKi | 17884974 |
| COX-2 PTGS2 |
Inhibition | 4.590000152587891 pKi | 17884974 |
| TRPV4 TRPV4 |
Inhibition | 6.519999980926514 pIC50 | 32051870 |
SOURCE
PharmGKB
60 phenotype rows
Pharmacogenomics
Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.
TLR4 (PA36552) rs1927911
Genotypes AA + AG is associated with increased likelihood of Asthma when treated with acetaminophen in children as compared to genotype GG.
Evidence: -; PMID 24851022
OPRM1 (PA31945) rs1799971
Genotype AA is associated with increased response to acetaminophen and tramadol in people with neuropathic pain as compared to genotypes AG + GG.
Evidence: -; PMID 21837673
CYP3A5 (PA131) rs776746
Allele C is not associated with metabolism of acetaminophen in healthy individuals as compared to allele T.
Evidence: -; PMID 28663312
ABCG2 (PA390) rs2231142
Genotype GT is not associated with clearance of acetaminophen as compared to genotype GG.
Evidence: -; PMID 21241071
UGT1A (PA37173) rs10929303
Genotypes CT + TT are associated with decreased risk of Liver Failure, Acute when treated with acetaminophen as compared to genotype CC.
Evidence: -; PMID 23408116
UGT1A (PA37173) rs1042640
Genotypes CG + GG are associated with decreased risk of Liver Failure, Acute when treated with acetaminophen as compared to genotype CC.
Evidence: -; PMID 23408116
UGT2B15 (PA37188) UGT2B15*1, UGT2B15*2
UGT2B15 *2 is associated with decreased metabolism of acetaminophen in healthy individuals as compared to UGT2B15 *1.
Evidence: -; PMID 21666065
UGT1A6 (PA37181) UGT1A6*1a, UGT1A6*2a
UGT1A6 *2a is associated with increased clearance of acetaminophen in people with beta-Thalassemia as compared to UGT1A6 *1a.
Evidence: -; PMID 17164591
UGT1A6 (PA37181) UGT1A6*1a, UGT1A6*2a
UGT1A6 *2a/*2a + *1a/*2a is associated with increased metabolism of acetaminophen in healthy individuals as compared to UGT1A6 *1a.
Evidence: -; PMID 21666065
CYP2D6 (PA128) CYP2D6*1
CYP2D6 *1/*1 is associated with inhibition of metabolism when treated with acetaminophen, codeine and levomepromazine in people with Back Pain.
Evidence: -; PMID 19308365
UGT1A1 (PA420) UGT1A1*1, UGT1A1*28
UGT1A1 *28 is not associated with metabolism of acetaminophen in healthy individuals as compared to UGT1A1 *1.
Evidence: -; PMID 15180166
HLA-C (PA35057) HLA-C*08:01
HLA-C *08:01 is not associated with increased likelihood of Stevens-Johnson Syndrome when treated with acetaminophen.
Evidence: -; PMID 21545408
HLA-C (PA35057) HLA-C*03:02
HLA-C *03:02 is not associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with acetaminophen.
Evidence: -; PMID 21545408
HLA-DQB1 (PA35068) HLA-DQB1*02:02
HLA-DQB1 *02:02 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with acetaminophen.
Evidence: -; PMID 21545408
HLA-DRB1 (PA35072) HLA-DRB1*15:02:01
HLA-DRB1 *15:02:01 is not associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with acetaminophen.
Evidence: -; PMID 21545408
HLA-DRB1 (PA35072) HLA-DRB1*04:05:01
HLA-DRB1 *04:05:01 is not associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with acetaminophen.
Evidence: -; PMID 21545408
HLA-DRB1 (PA35072) HLA-DRB1*11:01:01
HLA-DRB1 *11:01:01 is not associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with acetaminophen.
Evidence: -; PMID 21545408
HLA-DRB1 (PA35072) HLA-DRB1*13:02:01
HLA-DRB1 *13:02:01 is not associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with acetaminophen.
Evidence: -; PMID 21545408
HLA-B (PA35056) HLA-B*58:01
HLA-B *58:01 is not associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with acetaminophen.
Evidence: -; PMID 21545408
HLA-A (PA35055) HLA-A*33:03
HLA-A *33:03 is not associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when treated with acetaminophen.
Evidence: -; PMID 21545408
SULT1A1 (PA343) rs1042028
Genotype CC is associated with increased response to acetaminophen in healthy individuals as compared to genotypes CT + TT.
Evidence: -; PMID 30908574
UGT2B15 (PA37188) rs1902023
Genotype AA is associated with increased metabolism of acetaminophen in healthy individuals as compared to genotypes AC + CC.
Evidence: -; PMID 28663312
PLCG1 (PA33392) rs2228246
Allele G is associated with increased risk of Angioedema when treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives and Pyrazolones as compared to genotype AA.
Evidence: -; PMID 26398624
PLA2G4A (PA271) rs12746200
Allele G is associated with increased risk of Urticaria when treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones as compared to genotype AA.
Evidence: -; PMID 26398624
TRPV1 (PA37329) rs224534
Genotypes AA + AG is associated with increased response to acetaminophen in healthy individuals as compared to genotype GG.
Evidence: -; PMID 30908574
- rs9933632
Genotypes GT + TT are associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with acetaminophen, ibuprofen, loxoprofen or salicylamide as compared to genotype GG.
Evidence: -; PMID 29239905
- rs6500265
Genotypes CT + TT are associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with acetaminophen, ibuprofen, loxoprofen or salicylamide as compared to genotype CC.
Evidence: -; PMID 29239905
UGT1A9 (PA419) rs8330
Genotypes CG + GG is associated with decreased risk of Liver Failure, Acute when treated with acetaminophen as compared to genotype CC.
Evidence: -; PMID 24104197
CYP3A5 (PA131) rs776746
Genotype CT is associated with increased risk of Liver Failure, Acute when treated with acetaminophen as compared to genotype CC.
Evidence: -; PMID 24104197
CD44 (PA26221) rs1467558
Genotype TT is associated with increased risk of Liver Failure, Acute when treated with acetaminophen as compared to genotypes CC + CT.
Evidence: -; PMID 24104197
SOURCE
NLM RxNorm
14 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| ACETAMINOPHEN | 161 | SU | MTHSPL |
| Acetaminophen | 161 | SU | MTHSPL |
| acetaminophen | 161 | SU | MTHSPL |
| acetaminophen | 161 | IN | RXNORM |
| Panadol | 202432 | BN | RXNORM |
| Tylenol | 202433 | BN | RXNORM |
| Anacin | 215256 | BN | RXNORM |
| Excedrin | 217020 | BN | RXNORM |
| Feverall | 217115 | BN | RXNORM |
| Norco | 218772 | BN | RXNORM |
| Redutemp | 219598 | BN | RXNORM |
| Tencon | 220211 | BN | RXNORM |
| Acephen | 225064 | BN | RXNORM |
| Ultracet | 353062 | BN | RXNORM |
SOURCE
SIDER
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abdominal discomfort | acetaminophen | LLT | C0232487 |
| Abdominal discomfort | acetaminophen | PT | C0232487 |
| Abdominal distension | acetaminophen | PT | C0000731 |
| Abdominal pain | acetaminophen | LLT | C0000737 |
| Abdominal pain | acetaminophen | PT | C0000737 |
| Acute angle-closure glaucoma | acetaminophen | LLT | C0154946 |
| Acute generalised exanthematous pustulosis | acetaminophen | LLT | C0877055 |
| Acute generalised exanthematous pustulosis | acetaminophen | PT | C0877055 |
| Acute hepatic failure | acetaminophen | LLT | C0162557 |
| Acute hepatic failure | acetaminophen | PT | C0162557 |
| Administration site reaction | acetaminophen | LLT | C0851536 |
| Administration site reaction | acetaminophen | PT | C0851536 |
| Agitation | acetaminophen | LLT | C0085631 |
| Agitation | acetaminophen | PT | C0085631 |
| Agranulocytosis | acetaminophen | LLT | C0001824 |
| Agranulocytosis | acetaminophen | PT | C0001824 |
| Alveolitis | acetaminophen | LLT | C0549493 |
| Alveolitis | acetaminophen | PT | C0549493 |
| Anaemia | acetaminophen | LLT | C0002871 |
| Anaemia | acetaminophen | PT | C0002871 |
| Anaemia postoperative | acetaminophen | LLT | C0877398 |
| Anaemia postoperative | acetaminophen | PT | C0877398 |
| Anaphylactic shock | acetaminophen | LLT | C0002792 |
| Anaphylactic shock | acetaminophen | PT | C0002792 |
| Angioedema | acetaminophen | LLT | C0002994 |
| Angioedema | acetaminophen | PT | C0002994 |
| Angiopathy | acetaminophen | LLT | C0042373 |
| Angiopathy | acetaminophen | PT | C0042373 |
| Angle closure glaucoma | acetaminophen | LLT | C0017605 |
| Angle closure glaucoma | acetaminophen | PT | C0017605 |
| Angle closure glaucoma | acetaminophen | PT | C0017605 |
| Anorexia | acetaminophen | LLT | C0003123 |
| Anxiety | acetaminophen | LLT | C0003467 |
| Anxiety | acetaminophen | PT | C0003467 |
| Aspartate aminotransferase increased | acetaminophen | LLT | C0151904 |
| Aspartate aminotransferase increased | acetaminophen | PT | C0151904 |
| Asthenia | acetaminophen | PT | C0004093 |
| Asthma | acetaminophen | LLT | C0004096 |
| Asthma | acetaminophen | PT | C0004096 |
| Atelectasis | acetaminophen | LLT | C0004144 |
| Atelectasis | acetaminophen | PT | C0004144 |
| Azotaemia | acetaminophen | PT | C0242528 |
| Balance disorder | acetaminophen | PT | C0575090 |
| Benign prostatic hyperplasia | acetaminophen | PT | C1704272 |
| Bladder neck obstruction | acetaminophen | LLT | C0005694 |
| Bladder neck obstruction | acetaminophen | PT | C0005694 |
| Blood and lymphatic system disorders | acetaminophen | - | C0851353 |
| Blood disorder | acetaminophen | LLT | C0018939 |
| Blood disorder | acetaminophen | PT | C0018939 |
| Blood pressure increased | acetaminophen | LLT | C0497247 |
| Blood pressure increased | acetaminophen | PT | C0497247 |
| Body temperature increased | acetaminophen | LLT | C0015967 |
| Body temperature increased | acetaminophen | PT | C0015967 |
| Breath sounds abnormal | acetaminophen | LLT | C0231856 |
| Breath sounds abnormal | acetaminophen | PT | C0231856 |
| Bronchospasm | acetaminophen | LLT | C0006266 |
| Bronchospasm | acetaminophen | PT | C0006266 |
| Cardiac disorder | acetaminophen | LLT | C0018799 |
| Cardiac disorder | acetaminophen | PT | C0018799 |
| Chest discomfort | acetaminophen | PT | C0235710 |
| Chest pain | acetaminophen | LLT | C0008031 |
| Chest pain | acetaminophen | PT | C0008031 |
| Chest tightness | acetaminophen | LLT | C0232292 |
| Chills | acetaminophen | PT | C0085593 |
| Coma | acetaminophen | LLT | C0009421 |
| Coma | acetaminophen | PT | C0009421 |
| Confusional state | acetaminophen | LLT | C0009676 |
| Confusional state | acetaminophen | PT | C0009676 |
| Connective tissue disorder | acetaminophen | LLT | C0009782 |
| Connective tissue disorder | acetaminophen | PT | C0009782 |
| Constipation | acetaminophen | LLT | C0009806 |
| Constipation | acetaminophen | PT | C0009806 |
| Convulsion | acetaminophen | LLT | C0036572 |
| Convulsion | acetaminophen | PT | C0036572 |
| Coordination abnormal | acetaminophen | LLT | C0520966 |
| Coordination abnormal | acetaminophen | PT | C0520966 |
| Cough | acetaminophen | LLT | C0010200 |
| Cough | acetaminophen | PT | C0010200 |
| Cutaneous hypersensitivity | acetaminophen | LLT | C0585186 |
| Cytolytic hepatitis | acetaminophen | LLT | C0919823 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Acetaminophen used for in pharmaceutical contexts?
Acetaminophen (CAS 103-90-2) appears in DailyMed active-ingredient label rows, including Pain Reliever, Daytime Cold and Flu Multi Symptom mini softgels, MAX relief junior Grape.
What are the known adverse events for Acetaminophen?
Acetaminophen has 27,587 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Toxicity to various agents, Overdose, Acute hepatic failure, Intentional overdose, Completed suicide. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Acetaminophen also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Acetaminophen with EU status "permitted".
What clinical phase is Acetaminophen in?
Acetaminophen is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Acetaminophen?
Acetaminophen has 27 bioactivity rows in this page query. Rendered target entries include Prostaglandin G/H synthase 2, Transient receptor potential cation channel subfamily V member 1, Nuclear receptor subfamily 1 group I member 3, Carbonic anhydrase 2, Carbonic anhydrase 1.